Paula Kroon

754 total citations
10 papers, 539 citations indexed

About

Paula Kroon is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Paula Kroon has authored 10 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Immunology. Recurrent topics in Paula Kroon's work include CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and FOXO transcription factor regulation (2 papers). Paula Kroon is often cited by papers focused on CAR-T cell therapy research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and FOXO transcription factor regulation (2 papers). Paula Kroon collaborates with scholars based in Netherlands, Austria and Spain. Paula Kroon's co-authors include Inge Verbrugge, Vincent M. Mann, Matthew Simms, Somsundaram Chettiar, Anne T. Collins, Norman J. Maitland, Greta Rodrigues, Pui‐Kai Li, Paul A. Berry and Deepak Bhasin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Paula Kroon

9 papers receiving 533 citations

Peers

Paula Kroon

ONCOL

MB

IMMUN

CR

PRM

Lotte Hiddingh United States

Carlos R. Gil Del Alcazar United States

Agnete S. T. Engelsen Norway

Donna Guo United States

Patrick Grierson United States

Daniele Runci Italy

Amy Saur Conway United States

Emily Pittman United States

Xiangdong Zhao China

Hecheng Zhu China

Lotte Hiddingh United States

Paula Kroon

203 ×0.7

ONCOL

214 ×0.8

MB

139 ×1.0

IMMUN

109 ×0.9

CR

88 ×0.9

PRM

Citations per year, relative to Paula Kroon Paula Kroon (= 1×) peers Lotte Hiddingh

Countries citing papers authored by Paula Kroon

Since Specialization

Citations

This map shows the geographic impact of Paula Kroon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Kroon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Kroon more than expected).

Fields of papers citing papers by Paula Kroon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Kroon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Kroon. The network helps show where Paula Kroon may publish in the future.

Co-authorship network of co-authors of Paula Kroon

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Kroon. A scholar is included among the top collaborators of Paula Kroon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Kroon. Paula Kroon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Ma, Jennifer, Xiangjun Kong, Paula Kroon, et al.. (2024). Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition.. Journal of Clinical Oncology. 42(16_suppl). 2560–2560.

2.

Ma, Jennifer, Xiangjun Kong, Paula Kroon, et al.. (2024). Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.. Journal of Clinical Oncology. 42(16_suppl). e14533–e14533. 2 indexed citations

3.

Kok, Lianne, Paula Kroon, Xiangjun Kong, et al.. (2022). 239 Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy. Regular and Young Investigator Award Abstracts. A253–A253. 1 indexed citations

4.

Marques, Carolina, Thomas Unterkircher, Paula Kroon, et al.. (2021). NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1. eLife. 10. 58 indexed citations

5.

Oldrini, Barbara, Quanhua Mu, Paula Kroon, et al.. (2020). MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nature Communications. 11(1). 3883–3883. 143 indexed citations

6.

Kroon, Paula, Marit M. van Buuren, Ton N. Schumacher, et al.. (2019). Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. Cancer Immunology Research. 7(4). 670–682. 41 indexed citations

7.

Kroon, Paula, Jules Gadiot, Alessia Gasparini, et al.. (2016). Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology Immunotherapy. 65(6). 753–763. 26 indexed citations

8.

Gadiot, Jules, Ekaterina S. Jordanova, Ruben Lacroix, et al.. (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology. 5(12). e1238557–e1238557. 120 indexed citations

9.

Song, Ji‐Ying, Jules Gadiot, Adriaan D. Bins, et al.. (2016). Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences. 17(12). 2149–2149. 3 indexed citations

10.

Kroon, Paula, Paul A. Berry, Michael J. Stower, et al.. (2013). JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells. Cancer Research. 73(16). 5288–5298. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact